Retinal tissue may degenerate for a number of reasons. Among them are: artery or vein occlusion, diabetic retinopathy, R.L.F./R.O.P. or disease (usually hereditary). Retinitis pigmentosa, retinoschisis, lattic degeneration, and macular degeneration are characterized by progressive types of retinal degeneration.
A team of researchers at Baylor College of Medicine and collaborating institutions has shed new light into the complexity of vitamin B12 diseases.
Inherited retinal degeneration can make even the most mundane tasks-;like cooking, driving and walking down the sidewalk-;difficult or impossible, and it can't be cured.
Scientists have discovered that gene therapy and the diabetes drug metformin may be potential treatments for late-onset retinal degeneration (L-ORD), a rare, blinding eye disease.
HyVIS, the European project coordinated by the IIT-Istituto Italiano di Tecnologia (Italian Institute of Technology), is about to start.
A novel computational platform developed by researchers from the University of Pittsburgh School of Medicine identifies top-performing viral vectors that could deliver gene therapies to the retina with maximum efficiency and precision.
Can coronavirus disease 2019 (COVID-19) affect the eye? New research suggests the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can enter the eye and infect photoreceptor and retinal ganglion cells. In addition, SARS-CoV-2 infection increases the expression of several inflammatory genes, including the cytokine interleukin 33 (IL33), which is linked to COVID-19 disease and retinal degeneration.
Nanoscope Technologies LLC, a biotechnology company developing gene therapies for treatment of retinal diseases, is featuring multiple scientific presentations highlighting its groundbreaking research on optical gene delivery for vision restoration and OCT-guided electrophysiology platforms for characterization of retinal degeneration and assessment of efficacy of cell-gene therapy at the 2021 ARVO annual (virtual) meeting, May 1-7.
An analysis of thousands of genomes from people with and without the rare eye disease known as MacTel has turned up more than a dozen gene variants that are likely causing the condition to develop and worsen for a significant share of patients.
Progressive vision loss, and eventually blindness, are the hallmarks of juvenile neuronal ceroid lipofuscinosis (JNCL) or CLN3-Batten disease.
An international consortium of researchers is developing a new method to bring eyes back to life from deceased body donors for clinical research purposes.
A new study by scientists at the University of Southampton has made a breakthrough that could help the search for treatments against age related sight loss.
A team of LSU Health New Orleans researchers reports for the first time that deleting one of the inhibitors of the RPE65 gene in a mouse model that carries a human disease mutation prevents degeneration of cone photoreceptors that are used for daytime high-resolution color vision.
Researchers from Florida Atlantic University's Schmidt College of Medicine hope to conquer a major limitation in the ability for scientists to engineer tissues for regenerative therapies for age-related and degenerative diseases.
Heidelberg neurobiologists decode central mechanism of degenerative processes in the brains of mouse models and develop new principle for therapeutic agents
Scientists from the John A. Moran Eye Center at the University of Utah have achieved another first in the field of connectomics, which studies the synaptic connections between neurons.
A team of researchers from LSU Health New Orleans Neuroscience Center of Excellence and the University of Copenhagen provides the first evidence that patients with ocular hypertension may exhibit superior antioxidant protection that promotes resistance to the elevated intraocular pressure associated with glaucoma.
Gene therapy to the inner retina prevented blindness in a mouse model of the neuro-degenerative disorder CLN3 Batten disease.
Researchers who made a knock-in mouse-model of the genetic disorder retinitis pigmentosa 59, or RP59, expected to see retinal degeneration and retinal thinning. As reported in the journal Cells, they surprisingly found none, calling into question the commonly accepted -- though never proved -- mechanism for RP59.
Santen Pharmaceutical Co., Ltd. and jCyte Inc. announced the conclusion of an exclusive licensing contract covering the development, registration and commercialisation rights in Japan, Asia and Europe to jCell, a first-in-class investigational therapy, currently in clinical development for retinitis pigmentosa.
The Nanoscope team has developed Multi-Characteristic Opsins to sensitize cells toward low level of white light so that vision is improved at ambient room light.